echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > UACR Health China|The Early Nephropathy Screening Program for Diabetic Patients Helps Early Diabetic Kidney Screening and Early Treatment!

    UACR Health China|The Early Nephropathy Screening Program for Diabetic Patients Helps Early Diabetic Kidney Screening and Early Treatment!

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    *Only for medical professionals to read for reference, escort the health of Chinese patients! The prevalence of diabetes in adults in China is as high as 12.
    8%, and it is increasing year by year [1], and the situation is very severe.

    Diabetes management has now been included in the 14th action goal of the "Healthy China Action (2019-2030)", and diabetic nephropathy (DKD), as the most common microvascular complication in diabetic patients, is also one of the main causes of death for patients.
    Its harmfulness should not be underestimated [2].

    Therefore, early prevention, early diagnosis, and early treatment of DKD are particularly important to delay the development of the disease and improve the quality of life of patients [2].

     In this context, the "Healthy China-Early Diabetic Nephropathy Screening Program (UACR)" national kick-off meeting was held.
    Many authoritative experts from the endocrinology field participated and shared the impact of the implementation of the UACR program on Chinese diabetic patients.
    Social Significance.

    The cause of DKD is complex, and comprehensive management is more important.
    The prevalence of diabetes is increasing, and the incidence of DKD is also increasing.
    However, its awareness and treatment rates are generally low.
    In this regard, Professor Mu Yiming of the Chinese People's Liberation Army General Hospital analyzed that this There are many reasons for this situation, such as the following: ■ Multiple factors can cause kidney disease, the incidence of DKD increases, and social and economic development has brought people better living conditions, and the problem of overweight/obesity has become increasingly serious.
    Resident Nutrition and Chronic Disease Status Report (2020)", the overweight and obesity rates of residents aged 18 and over in China are 34.
    3% and 16.
    4%, respectively, while the prevalence of diabetes among overweight and obese people in China is 12.
    8% and 18.
    5%, respectively.
    Much higher than the normal weight population (7.
    6%) [3].

     Professor Mu Yiming pointed out that the cause of DKD is very complicated.
    In addition to overweight/obesity and diabetes, other factors such as hypertension, dyslipidemia, other complications, drug abuse, etc.
    may cause kidney disease.

    Under the influence of many factors, kidney damage is "unpreventable", and the incidence of DKD is gradually increasing.

     ■ The progress of drug research has been slow, and the late start of clinical application, Professor Yoshiaki, pointed out that in terms of kidney protection, there were few drugs available in the past, and only renin-angiotensin-aldosterone system (RAAS) inhibitors.

    The relative lack of treatment drugs available to endocrinologists may also be a major reason for the relatively low treatment rate of DKD.

     Until the last few years, drugs related to kidney protection have made significant progress and development, gradually appearing hypoglycemic drugs that have been proven to improve the kidneys and/or cardiovascular outcomes, and then began to help patients with diabetes and heart and kidney diseases.
    Carry out reasonable and effective treatment, such as sodium-glucose cotransporter 2 inhibitor (SGLT-2i).

     ■ The public has a low awareness of diseases, and the popularization of knowledge needs to be strengthened.
    The social and economic development is changing with each passing day.
    Ordinary people have gradually increased their requirements for health, paying more attention to the management of diseases such as diabetes and hypertension, but they are often limited to the "main body" of the disease.
    , But not paying attention to the complications of related diseases.
    This may be related to the low penetration rate of related diseases and the poor awareness of the disease by the public.

     It is worth mentioning that in the Chinese population, indiscriminate use of drugs is also one of the problems that damage the kidneys in addition to diseases, such as taking a certain "kidney-tonifying medicine" by oneself for a long time, or insisting on taking certain health products.

    Professor Mu Yiming emphasized that there is no so-called "Kidney Nourishing Recipe".
    The best "Kidney Protecting Recipe" is to develop good living habits and actively treat the primary disease.

    UACR testing helps early detection and early treatment of DKD.
    Nowadays, people’s living standards are continuously improving, the average life expectancy is increasing, and the process of population aging and urbanization is accelerating.
    In this process, major chronic diseases represented by diabetes have gradually received attention.
    The treatment made diabetic patients physically and mentally exhausted, but also brought a huge family burden and social burden.

     Professor Mu Yiming emphasized that DKD should be detected and treated early to achieve early control, otherwise the later period will be more harmful and the economic burden will be heavier.

     Elevated urine albumin/creatinine ratio (UACR) is an early detection indicator of DKD kidney damage [4].

    Professor Mu Yiming mentioned that with the advancement of science and technology, the current UACR inspection technology and methods are becoming more and more advanced, the result feedback is fast and accurate, and the cost is gradually adjusted to the range that the public can afford.
    Therefore, in clinical testing The increasingly widespread application of DKD provides technical support for early detection of DKD.

     At the same time, Professor Mu Yoshiaki also pointed out that the UACR indicator is very sensitive: on the one hand, it can quickly identify the increase in proteinuria, which is conducive to early detection of kidney disease and timely intervention and treatment; on the other hand, due to its too sensitive characteristics, it is easy to cause results.
    For example, if you eat more protein or exercise more before the test, false positives may occur.
    Therefore, it is recommended to perform at least two UACR tests to avoid errors.

     In addition, the glomerular filtration rate is also a commonly used clinical indicator to detect whether the kidney is damaged, but in fact, each indicator has its own characteristics and should be selected in accordance with the actual situation in clinical use.

    UACR study-the first step to achieve "Healthy China 2030" Professor Yiming Mu pointed out that the current detection rate of diabetic nephropathy in China is generally low, mainly because more than half of diabetic nephropathy patients do not know their health status, even if After getting the diagnosis, only about half of the patients were able to seek the help of a doctor.

    Among them, there may be only half of the patients who have taken active measures to treat and are effectively controlled.
    In other words, out of 100 patients with diabetic nephropathy, only about 20 people may be able to receive effective treatment, regardless of whether it can be effectively prevented.
    complication.

    Therefore, Professor Mu Yiming proposed that early screening, early diagnosis, and early treatment are imminent for people at high risk of DKD.

     Professor Mu Yiming will also lead the team to conduct related research.
    Professor Mu Yiming mentioned that the main goal of this research is not to provide a clear treatment plan for DKD, but to grasp the incidence and incidence of DKD in the Chinese population.
    Key data such as factor ratio and drug treatment rate.

    The scientificity, authenticity, accuracy, and comprehensiveness of these data are conducive to the national government and clinical workers to carry out further work and take more targeted measures.

    Professor Mu Yiming called for the hope that through these data, the public can pay enough attention to diabetes and related complications, establish a healthy life concept, and help clinicians better carry out pre-screening work, and follow the guidelines for People with diabetes and complications should carry out timely and effective interventions to reduce the pain and burden of the disease.

    Summary The prevalence of adult diabetes in China is increasing year by year.
    Among them, DKD is one of the main complications of diabetes, and its harm cannot be underestimated.
    Early prevention, early diagnosis, and early treatment are needed to delay the development of DKD and improve the quality of life of patients.
    .

    UACR is an important early indicator of clinical detection of DKD.
    With the advancement of science and technology, its detection results are becoming faster and more accurate, and the cost is continuously reduced, which can better meet the needs of patients.

    The mother professor also emphasized that in order to avoid errors, it is recommended to perform at least 2 tests.

     Combined with the status quo of diabetes and complications in China, the UACR study can sort out the exact data related to the disease for government decision makers and clinicians, and provide reliable evidence support for follow-up in-depth research and further targeted measures, in order to make more diabetes and complications Benefits for patients with disease.

    Expert profile Professor Mu Yiming, director of the Department of Endocrinology, PLA General Hospital; chief physician, professor, doctoral tutor; former chairman of the Endocrinology Branch of the Chinese Medical Association; chairman of the Endocrinology Professional Committee of the PLA; chairman of the Endocrinology Professional Committee of the Beijing Medical Association; Vice President of Endocrinology and Metabolism Physician Branch of Chinese Medical Doctor Association; Deputy Editor-in-Chief of Chinese Journal of Endocrinology and Metabolism; Deputy Editor-in-Chief of Chinese Journal of Frontier Medicine; Deputy Editor-in-Chief of Journal of Practical Internal Medicine; Deputy Editor-in-Chief of Medical Journal of Chinese People's Liberation Army; Drug Evaluation Editor-in-chief of Magazine.

    References: [1]Yongze Li, et al.
    BMJ.
    2020;369:m997.
    [2]Han Limin, et al.
    Modern Medicine and Health.
    2021;37(03):404-407.
    [3] "Chinese Resident Nutrition and Chronic Disease Status Report (2020)" [4] National Kidney Foundation.
    American Journal of Kidney Diseases.
    2012;60(5):850-886.
    This material is provided by AstraZeneca and is only for reference by medical and health professionals.

    Approval number: CN-76405 Valid until: 2023-4-9 For submission/reprint/business cooperation, please contact: pengsanmei@yxj.
    org.
    cn  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.